Erasca recent share selloff overdone, says JPMorgan

JPMorgan analyst Anupam Rama believes the recent weakness in shares of Erasca (ERAS) is overdone. ERAS-0015 has potential for safety differentiation and looks efficacious in non-small cell lung cancer, the analyst tells investors in a research note. JPMorgan recommends buying the stock at current levels, saying Erasca has multiple catalysts over the next months. It keeps an Overweight rating on the name.